Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 9Leukemia, Myelomonocytic, Chronic 4Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Advanced Solid Neoplasm 2Thrombocytosis 1Thrombocythemia, Essential 1Solid Tumors 1Renal Insufficiency 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Liver Diseases 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Carboplatin 340Cisplatin 238Paclitaxel 203Radiotherapy 195Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 141Erlotinib Hydrochloride 107Etoposide 99Magnetic Resonance Spectroscopy 93Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 72durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49atezolizumab 42Irinotecan 42Radiation 40Topotecan 39Biopsy 39Standard of Care 38Cyclophosphamide 38Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × pevonedistat × Clear all
NCT03965689 2026-04-13

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

National Cancer Institute (NCI)

Phase 2 Active not recruiting
27 enrolled 13 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡